MedImmune an AstraZeneca (NYSE: AZN) subsidiary has licensed from Crucell (NASDAQ: CRXL) biologicals focused on hospital acquired bacterial infections. Note to Self: look at Methicillin-resistant Staphylococcus aureus market
Big Pharma 411 is a selfish blog...
I am aggregating easily sortable news and milestones in a single spot and, at times throwing in my two-cents. Please send all comments to me via email: arubenstein@rnaventures.com
No comments:
Post a Comment